Living with HIV: Understanding the Patient Experience and Appreciating the Science – Tweetorial #1




Provided by Integrity Continuing Education, Inc.

This program is being developed in collaboration with HealthHIV.


Supported by an educational grant from Gilead Sciences, Inc.


Human immunodeficiency virus (HIV) infection was first documented in the United States in 1981. Since that time, significant strides have been made in the prevention and treatment of the condition. Screening is paramount in identifying early infection and is now a routine component of care, and appropriate management with combination antiretroviral therapy (ART) extends patients’ lives, sometimes for many years. However, therapy is lifelong and complicated by pill burden, cost, adverse effects, drug interactions, and disparities. This Twitter-based tutorial will focus on disparities in HIV incidence, inequities in treatment of patients with HIV, and strategies to combat these challenges.


Federico Hinestrosa, MD, FACP, FIDSA
Assistant Professor
College of Medicine
University of Central Florida
Associate Medical Director
Orlando Immunology Center
Orlando, Florida


Onyema Ogbuagu, MD, FACP, FIDSA
Associate Professor of Medicine
Section of Infectious Diseases
Yale School of Medicine
New Haven, Connecticut


Release date: May 11, 2022
Expiration date: February 11, 2023
Estimated time to complete activity: 15 minutes



This educational activity has been designed to meet the needs of US-based HIV specialty clinicians and infectious disease physicians involved in managing care for patients who are at risk for or living with HIV.


Upon completion of this educational activity, participants should be able to:

  • Summarize HIV access and care disparities among different marginalized populations in order to provide resources and training to address the issue of health disparities
  • Implement strategies to overcome barriers to care for patients in the local HIV community
  • Select ART regimens that minimize drug-drug interactions and toxicities, support adherence, and consider patient and systemic factors including patient preference

There are no fees for participating and receiving CME credit for this activity. During the period of May 11, 2022 through February 11, 2023, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 100%.




Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Integrity Continuing Education, Inc. designates this Enduring material for a maximum of 0.25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or


Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Federico Hinestrosa, MD, FACP, FIDSA
Advisor: Gilead Sciences, Theratechnologies, ViiV
Speaker: AbbVie, Gilead Sciences, Theratechnologies, ViiV

Onyema Ogbuagu, MD, FACP, FIDSA
Advisor: Gilead Sciences, ViiV
Speaker: Gilead Sciences

Integrity Continuing Education, Inc. staff and others involved with the planning, development, and review of the content for this activity have no relevant financial relationships to disclose.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)


Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Continue to Pretest